PubMed Health⌕ Search

PubMed · 12669533

[Why do tumor cells avoid immune surveillance?].

Abstract

Why does cancer develop? What is the essence of premalignant lesions? My answer to these sacramental questions follows. I found out that hyperplastic and tumor nodules are immunologically privileged sites, like the anterior chamber of the eye or the hamster's retrobuccal sac. The antigens from the nodules do not provoke the body's immune reactions, unlike the same antigens from the extranodular tissue. On the other hand, both the autoantibodies and the killer-cells sensitized to this antigens are unable to react with that part of the cells possessing antigens, which are situated within the nodules and completely destroy the same cells in the extranodular tissue. Hyperplastic and tumor nodules are special sites where immunological surveillance is absent. It is because they have no lymphatic and so recirculation of immunocompetent cells through its territory is impossible. Thus, newborn malignant cells in these precancerous formations avoid the immunological control and survive, in contrast to the tissue with the normal structure. So, neoplastic processes will be free from immunological surveillance in the precancerous sites and will therefore be more likely to progress.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

V S Prokopchuk. 2002. [Why do tumor cells avoid immune surveillance?].. https://pubmed.ncbi.nlm.nih.gov/12669533/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Analysis of HLA class I specific antibodies in patients with failed allografts.

BACKGROUND: The goals of this study are first to determine the epitope specificity of donor specific antibody (DSA) in the serum of alloimmunized transplant patients with a failed renal graft; and second to understand the correlation between the development of DSA and nondonor specific antibody (NDSA). METHODS: The sera of 35 pretransplant panel reactive antibody (PRA)-negative patients with failed allografts were examined with single-antigen (SA) luminex beads to identify human leukocyte antigen (HLA)-A and -B antibodies. Potential HLA antibody epitopes were identified by using computer software and verified by absorption and elution from single-antigen cell lines. RESULTS: Twenty-seven patients developed donor-specific HLA-A and/or -B antibodies, while the remaining eight patients had only nondonor-specific HLA-A and/or -B antibodies. The DSA-positive patients also had a long list of NDSA. Sixty-eight percent of the reactions found in 27 recipients with DSA were attributable to 66 epitopes on the mismatched donor HLA molecule. All 39 NDSA in eight patients with only NDSA shared 17 epitopes within positive allele specificities. By absorption and elution using recombinant cell lines having a single HLA specificity, we confirmed the epitopes involved in three patients. CONCLUSION: Development of most NDSA in patients with failed allografts is likely due to sharing epitopes with DSA and/or other NDSA.

Antibody Formation↗

Human keratinocyte Toll-like receptors promote distinct immune responses.

It has been well established that Toll-like receptors (TLRs) are expressed by keratinocytes and respond to their respective ligands to initiate immune responses. However, it appears that keratinocytes, via differential activation of TLRs, may play a key role in determining the type of subsequent cutaneous immune response generated against a particular pathogen.

Antibody Formation↗